ENTX Entera Bio Ltd: Enterprise Value to EBITDA Ratio
Market fluctuations in Entera Bio Ltd. (ENTX) shares reflect an EV/EBITDA valuation of 0.00, which correlates with partnerships to develop tablet versions of injectable drugs for the treatment of hormonal imbalances and osteoporosis. The business relies on patent prospects in the absence of current profits. Meanwhile, the project possesses high macro-resilience, as progress depends on FDA verdicts rather than economic cycles.
Comprehensive metric breakdowns and analytics for enterabio.com (ENTX)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
ENTX - Company Net Income|Expected Profit Entera Bio Ltd.|ENTX - Company Value to Net Income|Forward P/E Multiple Entera Bio|ENTX - PEG Multiple|Enterprise Value to EBITDA Ratio ENTX|ENTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Entera Bio|ENTX - Earnings per share for the last twelve months|Quarterly EPS earnings growth enterabio.com|ENTX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Entera Bio Ltd.
Initial company analysis:ENTX (Entera Bio Corp)
Logistics optimization through the elimination of the cold chain increases the margins of Entera Bio Ltd. (ENTX), which directly impacts operating profit. By analyzing fluctuations in the company's EV/EBITDA ratio, investors assess the enterprise value relative to its ability to generate cash flow, determining the real attractiveness of the assets and their resilience to credit risks over the long term.
Competitor analysis for Entera Bio Ltd.
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|MannKind Corp (MNKD) - Company Value to EBITDA|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX (Pacira Corp) - Enterprise Value to Operating Income Before Depreciation|SPRY (ARS Pharmaceuticals) - Enterprise Value to EBITDA Ratio|TBPH: Enterprise Value to Operating Income Before Depreciation Ratio|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA scPharma SCPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|TNXP (Tonix Pharmaceuticals Holding) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SXTC (China SXT Pharmaceuticals, Inc.)|EV/EBITDA Multiple Eupraxia Pharmaceuticals, Inc. EPRX|BHST: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation EXOZ (Invizyne Technologies)|ORMP: EV/EBITDA Multiple|HYFT (MindWalk Therapeutics) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ABVC (ABVC BioPharma) - EV/EBITDA Multiple|cumberlandpharma.com (CPIX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Quantum BioPharma (QNTM)|FGEN - Company Value to EBITDA|Telomir Pharma - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RANI|SNYR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RLYB: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LEXX (lexariabioscience.com) - Enterprise Value to EBITDA Ratio|PULM: Enterprise Value to Operating Income Before Depreciation Ratio|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation APM (Aptorum)|Enterprise Value to EBITDA Ratio LYRA (Lyra Therapeutics, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio impactbiomedinc.com|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|cbdMD Inc. (YCBD) - Company Value to EBITDA|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO (Altamira Therapeutics) - Enterprise Value to Operating Income Before Depreciation|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|OPTN: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio PIRS|Enterprise Value to Operating Income Before Depreciation PROC (Procaps Group)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|QLI: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|Business Value to Operating Income Before Depreciation TFFP
